TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with histologically confirmed breast cancer with known human epidermal receptor-2 (HER2) and hormone status~* Newly diagnosed CNS metastasis with at least one brain lesion measuring greater than or equal to (\>/=) 1 centimeter (cm) or two lesions measuring \>/= 0.5 to less than (\<) 1 cm in longest dimension~* Participant not eligible for or refusing surgery or stereotactic radiosurgery~* Eastern cooperative oncology group (EOCG) performance status 0 to 2~Exclusion Criteria:~* Prior treatment of brain metastases~* Leptomeningeal disease~* Known contra-indication to radiotherapy or magnetic resonance imaging (MRI) or capecitabine

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- WBRT Followed by Standard of Care (Type: ACTIVE_COMPARATOR): Participants will receive 3000 centi-Gray (cGy) WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) followed by standard of care therapy at the discretion of the treating oncologist starting no earlier than 2 weeks after completion of WBRT. The participants will be followed during the treatment until the halting of standard of care for any reason (central nervous system \[CNS\] or extra-cranial tumor progression, unacceptable toxicity, change of therapeutic strategy, withdrawal of participant consent, or death).
- WBRT+Capecitabine Followed by Capecitabine Maintenance (Type: EXPERIMENTAL): Participants will receive 3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction) concurrent with capecitabine 825 milligrams per square meter (mg/m\^2) orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by capecitabine 1000 mg/m\^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2, one week after completion of WBRT and continuing until the halting of capecitabine for any reason (CNS or extra-cranial progression, unacceptable toxicity, withdrawal of participant consent or death).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Complex Wounds Using a Constant Tension External Tissue Expander

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or greater~* Has soft tissue wound(s) that are unable to be closed primarily~Exclusion Criteria:~* Age less than 18~* Has wound(s) that can be closed primarily~* Infected wound~* Unable to comply with protocol~* Prior radiation treatment to skin or soft tissues in the area of the wound~* Friable wound margins

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DermaClose Group (Type: EXPERIMENTAL): DermaClose device applied to complex soft-tissue wound, with or without negative pressure wound therapy, and prospectively followed for primary and secondary outcomes for one year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Women aged 12-55 years who have a uterus and at least one functioning ovary.~Women with any active uterine bleeding more than spotting~Diagnosed with bone marrow failure, and other disease that require treatment with chemotherapy or stem cell transplantation with platelet counts less than 50,000 microliters at study entry~Do not desire pregnancy for the duration of the study.~Willing and able to give informed consent.~Willing and able to comply with study requirements.~EXCLUSION CRITERIA:~Age less than 12 years~Postmenopausal women~Hormone level in menopausal range: Follicle Stimulating Hormone greater than 40 IU/L, E (2) less than 20 pg/ml~History of liver disease that precludes OCP use~History of thrombosis, thromboembolism and/or thrombophilia.~Currently on 2 or more tablets of any oral contraceptive pills per day at study entry~Having 2 or more depo medroxyprogesterone acetate injections in the past 12 months or having depo medroxyprogesterone acetate injection in the past 90 days~Leuprolide acetate injection in the past 30 days~Smoker over the age of 35~Women with estrogen dependent tumor e.g. breast cancer.~Pregnancy.~Underlying sickle cell anemia~Women who are taking chemotherapeutic agents known to cause ovarian failure such as alkylating agents~Allergy to any medication in this protocol

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Lo-ovral (Type: ACTIVE_COMPARATOR): 1 tablet of lo-ovral is administered twice a day
- sugar pill (Type: PLACEBO_COMPARATOR): Sugar pill was provided as a placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Effects of Sublingual Sufentanil 30 µg on Postoperative Recovery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 years or older;~* Scheduled for elective knee arthroscopy without anticipated ligamentous repair;~* Planned general anesthesia without a regional block or wound infiltration with local anesthesia;~* Planned day-of-surgery discharge.~Exclusion Criteria:~* Opioid tolerance defined by ≥15 mg of oral morphine daily or equianalgesic dose of another opioid within 30 days of surgery;~* Known hypersensitivity to sufentanil or components of DSUVIA;~* Patients with an allergy or hypersensitivity to opioids;~* Pregnancy or actively breastfeeding;~* Patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 14 days of the first dose of study drug;~* Patients with a medical condition that, in the Investigator's opinion, could adversely impact the patient's participation or safety, conduct of the study, or interfere with the pain assessments, including chronic pain or active infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: ACTIVE_COMPARATOR): 30 µg tablet of sublingual sufentanil preoperatively and fentanyl placebo at induction of anesthesia.
- Control Group (Type: PLACEBO_COMPARATOR): placebo sublingual sufentanil preoperatively and 50 µg fentanyl at induction of anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 to 65 years, who require treatment for an acute episode of schizophrenia/schizoaffective disorder as judged by their doctor~Exclusion Criteria:~* Significant and unstable conditions of hear, circulation, blood, liver, kidney; malignancies (cancer); diabetes (mellitus); history of fits or fainting. Resistance to antipsychotic medication. Current alcohol/drug abuse. Pregnant/breast feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* metastatic urothelial cancer;~* disease progression during or after 1 prior platinum-based chemotherapy;~* measurable disease;~* HER2 overexpression (IHC \[2+\] or \[3+\]).~Exclusion Criteria:~* concomitant chemotherapy or immunotherapy;~* active or uncontrolled infection;~* solely CNS metastases;~* clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea;~* co-existing malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Monotherapy (Type: EXPERIMENTAL): Participants received an initial dose of trastuzumab 4 milligrams per kilogram (mg/kg) intravenously (IV) on Day 1, followed by weekly doses of 2 mg/kg IV beginning on Day 8 and continuing for up to 37 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cerebrospinal Fluid Pharmacokinetics of Daptomycin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Adults with suspected EVD related meningitis or ventriculitis who already have an external ventricular drain placed, as part of standard clinical care for CSF drainage, and whose clinicians plan to start antibiotics. There should be a clinical indication for the EVD to be in place for ≥ 72 hrs. An intravenous line which can be accessed for blood draws should be present.~Exclusion Criteria:~Age less than 18 years of age Patient is a woman who is pregnant or lactating Allergies or prior adverse reactions to daptomycin, which would preclude its use.~Elevated CK levels (\>500). Inability to obtain informed consent or get proxy consent. Patients on CRRT (continuous renal replacement therapies) or on dialysis Patients with an estimated CrCl \<30 cc/min as estimated by MDRD at base line. Patients with a BMI \>30 Any medical condition leading to a life expectancy of \< 48 hours, as determined by the clinician.~Patient who have received a dose of daptomycin in the last 7 days. Patients is participating in other studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- open label (Type: OTHER): patients meeting entry criteria enrolled and pk samples obtained around dosing of daptomycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed melanoma~  * Stage III or IV disease~* Must have at least two resectable tumors or a tumor large enough to undergo pre-treatment core needle biopsy~* Must be eligible for resection of disease with curative or palliative intent~PATIENT CHARACTERISTICS:~* ECOG performance status 0 or 1~* ANC ≥ 1,000/mm³~* Platelet count ≥ 50,000/mm³~* AST/ALT ≤ 3 times upper limit of normal (ULN)~* Total bilirubin normal~* Calculated creatinine clearance ≥ 50 mL/min~* INR ≤ 25% of ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 48 hours after completion of study treatment~* No history of allergic reaction to riluzole or similar compounds~* No known history of hepatitis B or C~PRIOR CONCURRENT THERAPY:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects over 18 years old, inclusive~* Has a known childhood diagnosis of classic CAH due to 21-hydroxylase deficiency based on genetic mutation in CYP21A2 and/or documented elevated 17-OHP and currently treated with HC, HC acetate, prednisone, prednisolone, methylprednisolone (or a combination of the aforementioned GCs)~* Has been on a stable supraphysiologic dose of GC replacement ≥15 mg/day and ≤60 mg/day in HC equivalents~* For subjects with the salt-wasting form of CAH, subject has been on a stable dose of mineralocorticoid replacement for ≥1 month before screening~Exclusion Criteria:~* Has a known or suspected diagnosis of any other known form of classic CAH (not due to 21 hydroxylase deficiency)~* Has a history that includes bilateral adrenalectomy or hypopituitarism~* Has a history of allergy or hypersensitivity to Tildacerfont, any of its excipients, or any other CRF1 receptor antagonist~* Current treatment with dexamethasone as GC therapy for CAH. Prior treatment with dexamethasone is allowed as long as the transition to an alternative GC regimen (eg, HC, prednisone, or prednisolone) has resulted in a stable dose of GC replacement for ≥1 month before screening.~* Shows clinical signs or symptoms of adrenal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tildacerfont Group 1 (Type: EXPERIMENTAL): Tildacerfont administered daily via oral tablet for 12 weeks at dose level 1
- Tildacerfont Group 2 (Type: EXPERIMENTAL): Tildacerfont administered daily via oral tablet for 12 weeks at dose level 2
- Tildacerfont Group 3 (Type: EXPERIMENTAL): Tildacerfont administered daily via oral tablet for 70 weeks at dose level 3
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered daily via oral tablet for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with refractory overactive bladder symptoms, failing a credible behavioral therapy intervention and medical therapy or not tolerating medical therapy. Patients who are on medical therapy will stop the medical therapy for at least 2 weeks prior to botulinum toxin A treatment in the study~* Female ≥ 18 years old~* Desires further treatment for OAB symptoms.~* Express understanding and ability to perform clean intermittent self-catheterization (CISC) if required.~* Ability to consent~* Ability to complete all study related items and interviews~Exclusion Criteria:~* Post void residual urine volume \> 150 mL as assessed by catheter or ultrasound~* History of intradetrusor botulinum toxin A injection~* History of or current cancer of the genitourinary or gynecology tract~* Neurogenic bladder~* Interstitial cystitis~* Current urinary tract infection (can be treated and re-considered for study)~* Current active sacral neuromodulation device~* Non-English speaking~* History of chronic pelvic pain~* Hematuria not previously evaluated

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Botulinum toxin A alone group (Type: ACTIVE_COMPARATOR): Just the intradetrusor injection of 100 units of botulinum toxin A alone
- Hydrodistention group (Type: EXPERIMENTAL): Hydrodistention at a pressure of 80 cm H2O for 5 minutes, prior to the intradetrusor injection of 100 units of botulinum toxin A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperglycemia in Surgical Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be enrolled at one of the following centers: the LBJ General Hospital (UT-Houston), the Ben Taub General Hospital (Baylor Houston), The Methodist Hospital (Texas Medical Center), or the University of Texas Health Science Center at San Antonio and the Brooke Army Medical Center.~* We will attempt to enroll all eligible patients with a diagnosis of a necrotizing soft tissue infection (NSTI), including Fournier's gangrene, confirmed in the operating room regardless of age, ethnicity or gender.~Exclusion Criteria:~* Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Strict glycemic control with a blood glucose target range of 80-110 mg/dL
- 2 (Type: OTHER): Conventional glycemic control with blood glucose target range of 110-140 mg/dL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any woman with prior SCAD who is at least 3 months out from her SCAD and has ongoing symptoms of chest pain.~* Females of child-bearing age must have a negative pregnancy test at enrollment~* Coronary Flow Reserve(CFR) \< 3.0~Exclusion Criteria:~* Renal dysfunction with Glomerular Filtration Rate \<50 ml/min~* Patients not willing to undergo coronary angiography~* Patients with a prior intolerance or allergy to rosuvastatin or ramipril~* Inability to perform CRT or CFR \>3.0~* Obstructive coronary artery disease (stenosis \>50% in any artery) or residual dissection \>50% with distal flow abnormalities

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosuvastatin, placebo (Type: EXPERIMENTAL): rosuvastatin 10-20mg daily or placebo (suggested dose of 10mg for Asians, and 20mg for others)
- Ramipril, placebo (Type: EXPERIMENTAL): ramipril (starting dose of ramipril at 5mg daily titrating up to 10mg daily at 1 week if tolerated) versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Dysfunction in Black Individuals: Roles of Nitric Oxide and Endothelin-1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Self-identification of their race and the race of their biological parents as being only Black (i.e., African American) or only White (i.e., Caucasian American)~* Born and raised in the United States~Exclusion Criteria:~* Mixed races~* Any chronic or ongoing disease~* Prescribed pharmacological treatment~* Smoking or tobacco use~* Obesity (body mass index \> 30 kg / m2)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Beetroot juice (Aim 1a) (Type: ACTIVE_COMPARATOR): Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a high (\~12.8 mmol) concentration of nitrates (James White Drinks, Suffolk, UK).
- Placebo (Aim 1a) (Type: PLACEBO_COMPARATOR): Upon arriving at the laboratory, participants will ingest 140 ml of beetroot juice containing a low concentration (\~0.0055 mmol) of nitrates (James White Drinks, Suffolk, UK).
- L-citrulline (Aim 1b) (Type: ACTIVE_COMPARATOR): Participants will receive pills containing 3 g of L-citrulline (Superior Labs, Park City, UT) to take twice daily for 7 days before the study visit.
- Placebo (Aim 1b) (Type: PLACEBO_COMPARATOR): Participants will receive pills containing a placebo to take twice daily for 7 days before the study visit.
- Sildenafil (Aim 1c) (Type: ACTIVE_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing Sildenafil (100 mg), an inhibitor of phosphodiesterase 5.
- Placebo (Aim 1c) (Type: PLACEBO_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.
- Bosentan (Aim 2) (Type: ACTIVE_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.
- Placebo (Aim 2) (Type: PLACEBO_COMPARATOR): Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy